Molecular Profiling of Advanced Biliary Tract Cancers (COMPASS-B-MUHC)

  • STATUS
    Recruiting
  • End date
    Apr 13, 2024
  • participants needed
    40
  • sponsor
    McGill University Health Centre/Research Institute of the McGill University Health Centre
Updated on 3 March 2022
measurable disease
gemcitabine
palliative care
advanced biliary tract carcinoma
biliary cancer
biliary tract cancer

Summary

Biliary tract cancer (BTC) accounts for <1% of all cancers, but remains a highly fatal malignancy. Surgical resection is the only hope for cure, but most patients present with advanced disease when curative-intent surgery is not possible. The therapeutic options for patients with advanced disease are limited, primarily to chemotherapeutic regimens, which are based on empiric evidence without the use of biomarkers. These current treatment strategies have been largely ineffective in controlling the disease, resulting in poor survival outcomes of less than 1 year. An understanding of the molecular characteristics of biliary tract cancer may enable stratification of patients into therapies that target specific molecular alterations with greater efficacies and improved clinical outcomes. This study aims to investigate the feasibility and clinical utility of prospective molecular profiling of advanced biliary tract cancer. The primary endpoint of this study is to demonstrate the feasibility of returning whole genome sequencing results within 8 weeks of tumour biopsy for second-line treatment consideration (n=30 patients). In parallel, tumour whole transcriptome sequencing will be performed to identify actionable molecular alterations (e.g., fusion transcripts). Once the primary endpoint is met, the study will be expanded. Current funding allows expansion to 40 patients in total.

Details
Condition Biliary Tract Cancer
Treatment Tumour and germline molecular profiling
Clinical Study IdentifierNCT04318834
SponsorMcGill University Health Centre/Research Institute of the McGill University Health Centre
Last Modified on3 March 2022

Eligibility

Yes No Not Sure

Inclusion Criteria

Patients must have a histological or radiological diagnosis of inoperable or metastatic BTC
Patient must have a tumour that is amenable to a core needle biopsy
Patients must have a measurable lesion by RECIST 1.1 in addition to the lesion that is going to be biopsied
Patients must be fit to safely undergo a tumour biopsy as judged by the investigator
Eastern Cooperative Group (ECOG) performance status 1
Life expectancy of greater than 90 days
Within 14 days of the proposed biopsy date, patients must have normal organ and marrow function
Patients must undergo systemic treatment with gemcitabine-based regimens as first-line standard systemic palliative treatment with or without other investigational agents within a clinical trial
Ability to understand and willing to sign a written informed consent document

Exclusion Criteria

Patients with one or more contraindications to tumour biopsy
Patients who have had any prior chemotherapy or other anti-cancer agent in the advanced stage setting
Patients who are currently on anti-cancer treatment
Patients with known brain metastases
Uncontrolled concurrent illness that would limit compliance with study requirements
Any other condition that would contraindicate the patient's participation due to safety concerns or compliance with clinical study procedures
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note